FDA Office of Generic Drugs acting director will be Cardio-Renal's Ganley.
This article was originally published in The Tan Sheet
Executive Summary
FDA GENERICS ACTING DIRECTOR WILL BE CARDIO-RENAL'S GANLEY, effective Aug. 21, FDA announced July 29. Charles Ganley, MD, of FDA's Cardio-Renal Drugs Division, will replace Douglas Sporn, who has been acting director of the Office of Generic Drugs since Robert Pollock left the position on Jan. 1 to work for Lachman Consulting Services.